For example, the CXCR4 receptor, primarily activated by CXCL12, can be used to direct nanoparticles specifically to cancers expressing CXCR4, such as ESCA, breast cancer and ovarian cancer (102). This evidence concerns the gene CXCL12 and breast carcinoma.